Adaptive and Genentech ink collaboration worth up to $2 billion

Washington, USA-based immunotherapy specialist Adaptive Biotechnologies has entered into a global development and licensing deal with Roche (ROG: SIX) subsidiary Genentech.

The firms will work together to develop, manufacture and commercialize novel T-cell therapies to treat a range of cancers, based around Adaptive’s proprietary TruTCR platform, a technology for discovery and immune profiling.

Adaptive says its platform can rapidly identify T-cell receptors (TCRs) for targeting specific neoantigens, which are proteins generated by tumor-specific mutations.